Last reviewed · How we verify
NCT03121469: RPOS+
Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer
NA trial testing Papillon +TM in Localized Breast Cancer in 28 participants. Completed in 10 June 2025.
30 November 2020
Quick facts
| Lead sponsor | Centre Antoine Lacassagne |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 25 October 2018 |
| Primary completion | 30 November 2020 |
| Estimated completion | 10 June 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- Papillon +TM
Conditions studied
- Localized Breast Cancer — all drugs for Localized Breast Cancer →
Sponsor
Centre Antoine Lacassagne — full company profile →
Who can join
60 and older, female only, with Localized Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase 1/2 study, open, monocenter, non-randomized
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Intraoperative Radiotherapy with Balloon-Based Electronic Brachytherapy System-A Systematic Review and First Bulgarian Experience in Breast Cancer Patients.
Kostova-Lefterova D, Vasileva-Slaveva M, Maslyankov S, Konsoulova A, et al · · 2021 · cited 4× · PMID 34677253 · DOI 10.3390/curroncol28050335
Verify or expand the search:
- PubMed search for NCT03121469
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Localized Breast Cancer
Currently open trials in the same condition.
- NCT07165756 — "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot S · recruiting
Other Centre Antoine Lacassagne trials
Trials by the same sponsor.
- NCT07429487 — Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fati · NA · not yet recruiting
- NCT06782451 — Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity · NA · recruiting
- NCT06606366 — Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplina · NA · recruiting
- NCT06400849 — Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy · NA · recruiting
- NCT06029218 — Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03121469 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Antoine Lacassagne
- Last refreshed: 23 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03121469.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing